Good research practices for measuring drug costs in cost-effectiveness analyses: An international perspective: The ISPOR drug cost task force report - Part VI

Value in Health

Volumn 13, Issue 1, 2010, Pages 28-33

  Shi, Lizheng ^a   Hodges, Meredith ^b   Drummond, Michael ^c   Ahn, Jeonghoon ^d   Li, Shu Chuen ^e   Hu, Shanlian ^f   Augustovski, Federico ^g   Hay, Joel W ^d   Smeeding, Jim ^h  

^a TULANE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF YORK   (United Kingdom)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF NEWCASTLE   (Australia)

^f FUDAN UNIVERSITY   (China)

^g INSTITUTE FOR CLINICAL EFFECTIVENESS AND HEALTH POLICY   (Argentina)

^h JestaRx Group   (United States)

Author keywords

Drug cost; Health technology assessment; Pharmacoeconomics

Indexed keywords

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG PACKAGING; HEALTH CARE SYSTEM; HUMAN; MEDICAL LITERATURE; MEDICAL PRACTICE; MEDICAL RESEARCH; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 72949120829     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00662.x     Document Type: Article

References (22)

1. Ridley DB. Price differentiation and transparency in the global pharmaceutical marketplace. Pharmacoeconomics 2005 23 : 661 668.
2. Drummond M. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Econ 1992 1 : 85 92.
3. Mrazek MF. Comparative approaches to pharmaceutical price regulations in the European Union. Croat Med J 2002 43 : 453 461.
4. Tilson L, McGowan B, Bennett K, Barry M. The high cost of medicines in Ireland. Eur J Health Econ. 2004 49 : 341 344.
5. Danzon PM, Kim JD. International price comparisons for pharmaceuticals. Measurement and policy issues. Pharmacoeconomics 1998 14 (Suppl. 1 115 128.
6. Lemgruber A, Santos V. The role of HTA in the price regulation of new medicines: the Brazilian experience. Health Technology Assessment International. Meeting (3rd: 2006: Adelaide, S. Aust.). Handb Health Technol Assess 2006 3 : 27.
7. Tobar F. Farmacoeconomía y regulación de medicamentos. Available from: http://www.federicotobar.com.ar/pdf/publicaciones/5.pdf [Accessed May 14, 2008 A, Regueiro A, Souto A, Augustovski F. Base de datos de costos sanitarios Argentinos/Health Care Costs Database - Argentina. Available from: http://www.iecs.org.ar/iecs-visor-publicacion.php?cod-publicacion= 146&origen-publicacion=publicaciones [Accessed May 15, 2008 D. The Australian pharmaceutical benefits scheme. Aust Prescr 1995 18 : 42 4.
8. Yip W, Hsiao W. Market watch: the Chinese health system at a crossroad. Health Aff 2008 27 : 460 468.
9. Wei Y. Health economic policy. In : Hu SL, ed., Health Economics: Basic Theory and Methods. Beijing : People's Health Press, 1996.
10. State Development and Reform Commission. A rule of drug differential price. Document No. 9, January 2005.
11. State Development and Reform Commission. Further consolidating the market order for pharmaceuticals and medical services. Document No. 912, 2006.
12. Yang L, Hu SL. The cost boundaries in the pharmacoeconomic evaluation. In : Hu SL, ed., A Study on Guidelines of Pharmacoeconomic Evaluation. Shanghai : The Fudan University Press, 2004.
13. National Health Insurance Corporation. Social security system of Korea - health security system. Available from: http://www.nhic.or.kr/eng/ [Accessed May 11, 2008 in Korean]. Available from: http://www.hira.or.kr [Accessed May 11, 2008 B, Bae E, Kim J. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance. Health Aff 2008 27 : 179 187.
14. Ministry of Health and Welfare (Korea). Media report, December 11, 2007 in Korean]. Available from: http://www.mw.go.kr/user.tdf [Accessed May 11, 2008 F. Design, analysis, and presentation of multinational economic studies: the need for guidance. Pharmacoeconomics 2008 20 : 75 90.
15. Reinharz D, Saldana VR, Follador W, Asche C. Pharmacoeconomic component of a clinical trial conducted in Latin America. Conceptual and empirical considerations. Inl J Technol Assess Health Care 2001 17 : 571 578.
16. Danzon PM, Furukawa MF. Prices and availability of pharmaceuticals: evidence from nine countries. Health Aff 2003 W3 : 521 536.
17. World Health Organization. Introduction to drug utilization research. 2003. Available from: http://www.who.int/medicines/areas/quality-safety/safety- efficacy/Drug%20utilization%20research.pdf [Accessed September 24, 2009 DA, Tilson L, Drummond MF. Estimating drug costs in economic evaluations in Ireland and the UK: an analysis of practice and research recommendations. Pharmacoeconomics 2009 27 : 635 643.
18. Barbieri M, Drummond M, Willke R, et al. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 2005 8 : 10 23.
19. Dickson M. The pricing of pharmaceuticals: an international comparison. Clin Ther 1992 12 : 604 610.
20. Drummond M, Jonsson B, Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 1997 40 : 199 215.
21. Danzon PM. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Finance Econ 2003 3 : 183 205.
22. International drug price indicators guide. Available from: http://erc.msh.org/dmpguide/pdf/DrugPriceGuide-2007-en.pdf [Accessed on January 26, 2008 K. OFT, VBP: QED? Health Econ 2007 16 : 545 558.